Search alternatives:
marked decrease » marked increase (Expand Search)
based decrease » caused decreased (Expand Search), based defense (Expand Search)
cases based » rates based (Expand Search), scores based (Expand Search), values based (Expand Search)
marked decrease » marked increase (Expand Search)
based decrease » caused decreased (Expand Search), based defense (Expand Search)
cases based » rates based (Expand Search), scores based (Expand Search), values based (Expand Search)
-
1
-
2
-
3
-
4
-
5
Base-case analysis.
Published 2025“…At a CET of 0.51 times GDP per capita (US$6,394.536), the base-case analysis showed that the incremental costs of AOM relative to PP1M after 10 years of treatment were US$1,926.373 with an incremental gain of 0.306 QALYs. …”
-
6
Group-level narrow- and broad-band spectral changes after hemispherotomy reveal a marked EEG slowing of the isolated cortex, robust across patients.
Published 2025“…This decrease was larger in the disconnected than in the contralateral cortex. …”
-
7
-
8
-
9
-
10
Biases in larger populations.
Published 2025“…<p>(<b>A</b>) Maximum absolute bias vs the number of neurons in the population for the Bayesian decoder. …”
-
11
-
12
-
13
-
14
-
15
-
16
Results of base case.
Published 2025“…Ischemic heart disease, heart failure, and myocardial infarction (stroke) decreased by 0.8%, 1.1%, and 4.7%, respectively. In the base-case analysis, IDegLira compared to the combined regimen shows an incremental cost of -34,254 CNY and an incremental QALYs of 0.436. …”
-
17
Base-case results.
Published 2024“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”
-
18
-
19
-
20
Base-case analysis results.
Published 2024“…</p><p>Results</p><p>In the base-case analysis, sintilimab plus IBI305 and chemotherapy had an ICER of $53,266.32/QALYs, exceeding the upper WTP threshold. …”